Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Amylin Pharmaceuticals, Inc. |
---|---|
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00039026 |
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: AC2993 (synthetic exendin-4) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 16 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2993-113 |
Study First Received: | June 6, 2002 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00039026 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Type 2 Diabetes Mellitis |
Hypoglycemic Agents Metabolic Diseases Exenatide Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Metabolic Diseases Exenatide Physiological Effects of Drugs Diabetes Mellitus, Type 2 |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions |